U.S. markets open in 6 hours 10 minutes

ADC Therapeutics SA (ADCT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
22.21-0.01 (-0.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close22.22
Open22.18
Bid12.04 x 800
Ask23.00 x 1400
Day's Range21.83 - 22.67
52 Week Range20.01 - 56.59
Volume275,796
Avg. Volume395,638
Market Cap1.704B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ADC Therapeutics SA (ADCT) Q1 2021 Earnings Call Transcript
    Motley Fool

    ADC Therapeutics SA (ADCT) Q1 2021 Earnings Call Transcript

    This morning, we issued a press release announcing our first-quarter 2021 financial results and business update. On today's call, Chris Martin, chief executive officer; Jennifer Herron, our chief commercial officer; Jay Feingold, chief medical officer; and Jenn Creel, chief financial officer, will discuss recent business highlights and review our first-quarter 2021 financial results before opening the call for questions.

  • ADC Therapeutics Stock Jumps On Scoring First FDA Approval For DLBCL Treatment
    Benzinga

    ADC Therapeutics Stock Jumps On Scoring First FDA Approval For DLBCL Treatment

    ADC Therapeutics SA (NYSE: ADCT) has scored an FDA approval for Zynlonta, formerly known as loncastuximab tesirine, as a solo treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two prior lines of therapy. Following a priority review in November with a review date of May 21, Zylonta’s accelerated nod comes a month ahead of schedule. The company will have to prove its clinical benefit in a confirmatory study to maintain its marketing approval. The approval comes just under a year after ADC went public, raising 3 million. The FDA endorsed the drug based on data from a Phase 2 trial, LOTIS 2. The drug turned in an overall response rate of 48.3%, and, for those who responded, the median duration of response was 10.3 months. More than 24% of patients experienced a complete response. Price Action: ADCT shares are up 5.72% at $24.58 in the premarket session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaRoche, AbbVie, Bristol-Myers Are Latest To Win European Medicines Agency's CHMP Positive OpinionBristol Myers' Psoriasis Med Deucravacitinib Superior To Amgen's Otezla, New Data Shows© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • ADC Therapeutics SA (ADCT) Q4 2020 Earnings Call Transcript
    Motley Fool

    ADC Therapeutics SA (ADCT) Q4 2020 Earnings Call Transcript

    This morning, we issued a press release announcing our fourth quarter and year-end 2020 financial results and business update. On today's call, Chris Martin, chief executive officer; Jay Feingold, chief medical officer; and Jen Creel, chief financial officer, will discuss recent business highlights and review our fourth quarter and year-end 2020 financial results. In addition, Jennifer Herron, our chief commercial officer, will be available for questions.